Clinical Trials Usher In Life-Saving New Treatments
A major recent advancement in the treatment of cardiovascular disease involves Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i).
Major clinical trials have shown that SGLT2i medications reduce major adverse cardiovascular events (such as heart attack, stroke, and cardiovascular death), hospitalization for heart failure, and all-cause death. SGLT2i also delay the onset of dialysis in renal disease.
SGLT2 inhibitors were initially intended for decreasing blood glucose in diabetes, but recent cardiovascular outcomes trials have revealed broader beneficial effects not only in patients with type 2 diabetes., but also in non-diabetic patients.
Major clinical trials have shown that SGLT2i medications reduce major adverse cardiovascular events (such as heart attack, stroke, and cardiovascular death), hospitalization for heart failure, and all-cause death. SGLT2i also delay the onset of dialysis in renal disease.
The cardiorenal benefits observed are consistent regardless of diabetic status, leading to the rapid adoption of SGLT2i therapy in cardiovascular and renal guidelines as well.
These developments offer new hope for patients and underscore the importance of ongoing research and clinical trials in uncovering new treatments and understanding disease mechanisms.
The National Heart Institute is part of the effort to bring innovative life-saving treatments and is currently recruiting patients for several ongoing trials involving conditions related to cardiovascular disease.
